loading...| Preferred Name |
Razuprotafib |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152161 |
| CAS_Registry |
1008510-37-9 |
| code |
C152161 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 |
| Contributing_Source |
FDA |
| DEFINITION |
A small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP), with potential vasculature stabilizing activity. Upon administration, razuprotafib targets, binds to and inhibits VE-PTP, which is a negative regulator of the endothelial cell (EC)-specific receptor tyrosine kinase (RTK) Tie2. This restores Tie2 activation, which may improve endothelial function and stabilize blood vessels. VE-PTP is upregulated in stressed endothelium associated with a variety of diseases. Tie2 plays an important role in endothelial function and vascular stability. A decrease in Tie2 activation leads to vascular leakage and inflammation. |
| FDA_UNII_Code |
0WAX4UT396 |
| FULL_SYN |
Razuprotafib RAZUPROTAFIB AKB 9778 AKB9778 AKB-9778 |
| label |
Razuprotafib |
| NCI_META_CUI |
CL553493 |
| Preferred_Name |
Razuprotafib |
| prefixIRI |
Thesaurus:C152161 |
| prefLabel |
Razuprotafib |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||